Advertisement

Topics

Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D

04:30 EDT 8 Aug 2017 | Medscape

Canagliflozin suppressed the increase in NT-proBNP and high-sensitivity troponin in older patients with type 2 diabetes, which may help shed some light on the beneficial CV effect of SGLT2 inhibitors.
Medscape Medical News

Original Article: Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D

NEXT ARTICLE

More From BioPortfolio on "Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D"

Quick Search
Advertisement